Cargando…

Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial

Detalles Bibliográficos
Autores principales:	Kondoh, Yasuhiro, Azuma, Arata, Tagawa, Jun, Homma, Sakae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328334/ https://www.ncbi.nlm.nih.gov/pubmed/32228231 http://dx.doi.org/10.1164/rccm.202003-0666LE

Ejemplares similares

Reply to Kobayashi et al.: Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Horita, Nobuyuki, et al.
Publicado: (2020)

Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Isshiki, Takuma, et al.
Publicado: (2019)

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
por: Ogura, Takashi, et al.
Publicado: (2023)

Takeshi Kasai: the health security thinker from Japan
por: Zarocostas, John
Publicado: (2019)

Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis
por: Nishioka, Yasuhiko, et al.
Publicado: (2021)

Dr. Takeshi Arimura: The present and future of proton therapy in Japan
por: Zhou, Silvia L., et al.
Publicado: (2018)

Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study
por: Awano, Nobuyasu, et al.
Publicado: (2022)

Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis
por: Kondoh, Yasuhiro, et al.
Publicado: (2017)

The Activities of Daily Living after an Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Koyama, Kazuya, et al.
Publicado: (2017)

Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
por: Kondoh, Yasuhiro, et al.
Publicado: (2022)

Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study
por: Abe, Mitsuhiro, et al.
Publicado: (2015)

Acute exacerbation of idiopathic pulmonary fibrosis triggered by Aspergillus empyema
por: Suzuki, Atsushi, et al.
Publicado: (2018)

Efficacy of recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis
por: Wang, Baojun, et al.
Publicado: (2020)

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment
por: Azuma, Arata, et al.
Publicado: (2011)

Fatal diffuse alveolar haemorrhage mimicking acute exacerbation in idiopathic pulmonary fibrosis treated with nintedanib
por: Sugino, Keishi, et al.
Publicado: (2017)

Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020)

Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin
por: Arai, Toru, et al.
Publicado: (2021)

Idiopathic Pulmonary Fibrosis: Treatment and Prognosis
por: Fujimoto, Hajime, et al.
Publicado: (2016)

The efficacy of recombinant human soluble thrombomodulin (rhsTM) treatment for acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
por: Kamiya, Hiroyuki, et al.
Publicado: (2020)

End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation
por: Akiyama, Norimichi, et al.
Publicado: (2022)

Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination
por: Bando, Tomohiro, et al.
Publicado: (2022)

New risk scoring system for predicting 3-month mortality after acute exacerbation of idiopathic pulmonary fibrosis
por: Sakamoto, Susumu, et al.
Publicado: (2022)

Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
por: Iwanami, Yuji, et al.
Publicado: (2022)

Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial
por: Hayakawa, Sho, et al.
Publicado: (2016)

Association of serum monomeric periostin level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
por: Shimizu, Hiroshige, et al.
Publicado: (2021)

Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
por: Shimizu, Hiroshige, et al.
Publicado: (2018)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center Study
por: Atsumi, Kenichiro, et al.
Publicado: (2017)

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial
por: Taniguchi, Hiroyuki, et al.
Publicado: (2011)

Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial
por: Arai, Toru, et al.
Publicado: (2020)

Acute exacerbation of combined pulmonary fibrosis and emphysema associated with Hermansky–Pudlak syndrome
por: Sugino, Keishi, et al.
Publicado: (2015)

Acute exacerbation of idiopathic pulmonary fibrosis induced by pertussis: the first case report
por: Hirai, Kuniaki, et al.
Publicado: (2019)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2021)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Kishaba, Tomoo
Publicado: (2019)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Lee, Joyce S., et al.
Publicado: (2013)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Lee, Joyce S., et al.
Publicado: (2018)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Kim, Dong Soon
Publicado: (2022)

Determinants of Six-Minute Walk Distance in Idiopathic Pulmonary Fibrosis and Idiopathic Pleuroparenchymal Fibroelastosis
por: Sato, Naofumi, et al.
Publicado: (2022)

Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan
por: Minegishi, Yuji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jeororcttkife9oijslstef7um